GROVELAND

Cancer Incidence by Sex, 1993 - 1997

Expected and Observed Case Counts, with Standardized Incidence Ratios

| | Exp | <u>Obs</u> | SIR | | Exp | <u>Obs</u> | <u>SIR</u> |
|--|-------|------------|-------------------------|------------------------|------|------------|------------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 2.92 | 3 | NC* | Male | 1.94 | 0 | NC* |
| Female | 1.08 | 0 | NC* | Female | 1.53 | 3 | NC* |
| Total | 4.00 | 3 | NC* | Total | 3.47 | 3 | NC* |
| Brain and Other Central Nervous System | | | | Multiple Myeloma | | | |
| Male | 1.11 | 0 | NC* | Male | 0.57 | 0 | NC* |
| Female | 0.91 | 0 | NC* | Female | 0.52 | 0 | NC* |
| Total | 2.02 | 0 | NC* | Total | 1.08 | 0 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin's Lymphoma | | | |
| Male | 0.20 | 0 | NC* | Male | 2.56 | 2 | NC* |
| Female | 19.46 | 21 | 108 | Female | 2.11 | 2 | NC* |
| Total | 19.66 | 21 | 107 | Total | 4.67 | 4 | NC* |
| Cervix Uteri | | | Oral Cavity and Pharynx | | | | |
| | | | | Male | 2.17 | 0 | NC* |
| Female | 1.29 | 1 | NC* | Female | 0.98 | 0 | NC* |
| | | | | Total | 3.15 | 0 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 7.48 | 10 | 134 | | | | |
| Female | 6.89 | 9 | 131 | Female | 2.37 | 0 | NC* |
| Total | 14.38 | 19 | 132 | | | | |
| Esophagus | | | | Pancreas | | | |
| Male | 1.15 | 1 | NC* | Male | 1.18 | 0 | NC* |
| Female | 0.35 | 0 | NC* | Female | 1.16 | 2 | NC* |

| Total | 1.50 | 1 | NC* | Total | 2.33 | 2 | NC* | |
|--|--------------|----|-----|-----------------|-------------------|---------|-----|--|
| Hodgkin's Disease | | | | Prostate | | | | |
| Male | 0.56 | 1 | NC* | Male | 18.96 | 24 | 127 | |
| Female | 0.41 | 3 | NC* | | | | | |
| Total | 0.96 | 4 | NC* | | | | | |
| Kidney and | Renal Pelvis | | | Stomach | | | | |
| Male | 1.89 | 2 | NC* | Male | 1.28 | 0 | NC* | |
| Female | 1.08 | 1 | NC* | Female | 0.74 | 1 | NC* | |
| Total | 2.97 | 3 | NC* | Total | 2.02 | 1 | NC* | |
| <u>Larynx</u> | | | | Testis | | | | |
| Male | 1.16 | 1 | NC* | Male | 0.80 | 2 | NC* | |
| Female | 0.32 | 0 | NC* | | | | | |
| Total | 1.48 | 1 | NC* | | | | | |
| Leukemia | | | | Thyroid | | | | |
| Male | 1.37 | 2 | NC* | Male | 0.42 | 0 | NC* | |
| Female | 1.01 | 1 | NC* | Female | 1.04 | 0 | NC* | |
| Total | 2.39 | 3 | NC* | Total | 1.46 | 0 | NC* | |
| Liver and Intrahepatic Bile Ducts | | | | Uteri, Corpu | ıs and Uter | us, NOS | | |
| Male | 0.64 | 0 | NC* | | | | | |
| Female | 0.24 | 2 | NC* | Female | 3.76 | 7 | 186 | |
| Total | 0.88 | 2 | NC* | | | | | |
| Lung and Bronchus | | | | All Sites / Ty | All Sites / Types | | | |
| Male | 10.07 | 10 | 99 | Male | 62.73 | 60 | 96 | |
| Female | 7.49 | 8 | 107 | Female | 58.86 | 65 | 110 | |
| Total | 17.56 | 18 | 102 | Total | 121.59 | 125 | 103 | |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for

this cancer

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- * = SIR and statistical significance not calculated when $\mathbf{Obs} < 5$
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels